Welcome to our dedicated page for BioNTech news (Ticker: BNTX), a resource for investors and traders seeking the latest updates and insights on BioNTech stock.
BioNTech SE reports recurring developments as a Germany-based biotechnology company whose ADSs trade on Nasdaq. Company news centers on oncology pipeline progress across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies, including lung cancer programs such as pumitamig and gotistobart, as well as COVID-19 vaccine activity tied to its commercial vaccine franchise.
Updates also cover quarterly and annual financial results, research and development spending, corporate presentations, capital allocation actions such as ADS repurchase authorizations, and shareholder meeting or governance matters. BioNTech news frequently links clinical data, partnership activity and operating priorities to its broader objective of building a multi-product biotechnology business.
Pfizer and BioNTech released updated topline results from their pivotal Phase 3 study on the BNT162b2 COVID-19 vaccine, reporting a 91.3% efficacy rate in preventing symptomatic COVID-19. The vaccine showed 100% effectiveness against severe disease according to the CDC and 95.3% against severe COVID-19 per the FDA. Safety data indicated a favorable profile from over 12,000 participants monitored for at least six months post-vaccination. These results bolster plans for a Biologics License Application to the FDA.
BioNTech (Nasdaq: BNTX) and Pfizer released positive results from a Phase 3 trial showing BNT162b2 vaccine achieved 100% efficacy in adolescents aged 12-15, exceeding the results of the 16-25 age group. The trial involved 2,260 participants, with no COVID-19 cases in the vaccinated group. The companies plan to submit the data to the FDA and EMA for Emergency Use Authorization expansion. Additionally, they initiated a Phase 1/2/3 study for children aged 6 months to 11 years, aiming to assess vaccine safety and immunogenicity.
Pfizer (PFE) and BioNTech (BNTX) announced the successful results of a Phase 3 trial for their COVID-19 vaccine BNT162b2, showing 100% efficacy in adolescents aged 12 to 15. The trial, involving 2,260 participants, indicated no COVID-19 cases in the vaccinated group compared to 18 in the placebo group. The companies intend to submit these findings for Emergency Use Authorization (EUA) modification in the US and similar requests globally. They are also advancing studies in younger children, with the goal of public vaccination before the next school year.
BioNTech SE (Nasdaq: BNTX) has achieved significant milestones with its BNT162b2 COVID-19 vaccine, now approved in over 65 countries. As of March 23, 2021, over 200 million doses have been supplied, with orders totaling 1.4 billion doses for 2021. The company anticipates expanding production capacity to 2.5 billion doses by year-end. Financially, BioNTech reported COVID-19 vaccine revenues of €270.5 million for the full year 2020 and ended the period with €1.2 billion in cash. The oncology pipeline is advancing with 13 candidates in 14 ongoing trials.
BioNTech SE announced the European Medicines Agency (EMA) approved its COVID-19 vaccine manufacturing at the Marburg facility, enhancing production capabilities to one billion doses annually. Due to operational efficiencies, an increase of 250 million doses is expected. 400 employees are currently at Marburg, with the first drug product batches anticipated for delivery in April. The facility is GMP-certified, ensuring high-quality drug production standards. BioNTech aims to produce up to 250 million doses of BNT162b2 in early 2021, catering to the growing global demand.
BioNTech (Nasdaq: BNTX) and Pfizer announced EMA approval for their COMIRNATY vaccine to be stored at -25°C to -15°C for two weeks. This flexibility enhances distribution, allowing storage in pharmacies and supporting decentralized vaccinations at general practitioners' offices across the EU. The approval aims to increase accessibility and reduce pressure on large vaccination centers.
Ugur Sahin, BioNTech's CEO, emphasized the importance of this milestone, while Albert Bourla, Pfizer's CEO, noted the collaborative efforts with regulatory agencies to enhance vaccine distribution.
BioNTech (Nasdaq: BNTX) is set to announce its financial results for the fourth quarter of 2020 on March 30, 2021. An investor call and webcast will take place at 8:00 a.m. EDT (2:00 p.m. CET) to discuss the results and provide a corporate update. The event will be accessible via the company’s website. BioNTech specializes in immunotherapy for cancer and serious diseases, leveraging mRNA technology and collaborating with major pharmaceutical companies.
The Israel Ministry of Health, Pfizer, and BioNTech released data showing significantly lower COVID-19 incidences in fully vaccinated individuals with the Pfizer-BioNTech vaccine. Findings indicate vaccinated individuals were 44 times less likely to develop symptomatic COVID-19 and 29 times less likely to die. Vaccine effectiveness was measured at 97% against symptomatic cases and severe outcomes, and 94% against asymptomatic infections. This comprehensive evidence supports ongoing global vaccination efforts amidst the pandemic.
The Israel Ministry of Health, Pfizer, and BioNTech announced significant findings from a real-world study showing a 97% effectiveness of the Pfizer-BioNTech COVID-19 Vaccine in preventing symptomatic COVID-19, severe cases, and deaths. This data, derived from health surveillance from January to March 2021, showcases the impact of Israel's vaccination efforts, particularly against the B.1.1.7 variant. Further, the vaccine demonstrated 94% effectiveness against asymptomatic infections, emphasizing its role in controlling the pandemic and supporting ongoing immunization campaigns globally.
Pfizer and BioNTech have initiated a Phase 1/2/3 trial to evaluate a third dose of their COVID-19 vaccine, BNT162b2, aimed at studying safety and immunogenicity against evolving SARS-CoV-2 variants. Participants who received the initial two doses will be offered a booster dose 6 to 12 months later. They are also in discussions with regulatory authorities for a variant-specific mRNA vaccine, potentially targeting the B.1.351 lineage. The companies seek to ensure robust immunity and prepare for possible future vaccine adaptations, with ongoing assessments expected over two years.